No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Maccura Biotechnology Co. Ltd. is an enterprise actively involved in the entire process of in vitro diagnostic (IVD) products, from their initial conceptualization and refinement (research and development) to mass production and market delivery. The company also extends related support services, catering to clientele within China and across global territories. Its diverse portfolio features immunoassay solutions, exemplified by chemiluminescence analyzers and their accompanying reagents. In the domain of clinical chemistry, Maccura furnishes reagents vital for evaluating a broad spectrum of physiological indicators, including hepatic and renal function, glucose metabolism, iron levels, specialized proteins, cardiac health, lipid profiles, and coagulation. Moreover, the firm supplies sophisticated clinical laboratory instrumentation, notably automatic hematology systems and both automated and semi-automated coagulation analyzers. The company's offerings further extend to include diagnostic tools for SARS-CoV-2 (COVID-19), such as nucleic acid detection kits and other related items. Additional products consist of glucometers, point-of-care testing (POCT) devices like fluorescence immunoassay analyzers and colloidal gold rapid test kits, molecular diagnostics (e.g., PCR kits), and a variety of pathology supplies. Maccura Biotechnology Co. Ltd. was established in 1994 and maintains its principal operations in Chengdu, China.
www.maccura.comNo one on the platform currently holds 300463.SZ.
No tracked institution reports a position in 300463.SZ as of their last filing.
No one on the platform has traded 300463.SZ yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -15.5% | -10.3% | ||||
| Profit Margin % | -1.7% | 11.6% | 15.2% | |||
| Free Cash Flow Margin % | -6.8% | 0.5% | -3.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $2.2B | -5.4% | $0.16 | $0.15–$0.17 | — | 1 |
| 2027 | $2.3B | +5.5% | $0.25 | $0.13–$0.37 | — | 2 |
| 2028 | $2.4B | +5.2% | $0.33 | $0.30–$0.36 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 0 of the last 5 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-31 | $0.42 | $0.04 | -90.0% |
| 2026-04-28 | $0.42 | $-0.12 | -128.6% |
| 2026-04-28 | $0.42 | $0.01 | -96.5% |
| 2025-04-28 | $0.16 | $-0.25 | -257.7% |
| 2024-10-22 | $0.18 | $0.13 | -27.8% |
| $8.11 |
| +0.75% |
| $5.8B |
| — |
| 300406.SZBeijing Strong Biotechnologies, Inc. | $11.18 | -0.27% | $6.6B | — |
| 300451.SZB-SOFT Co.,Ltd. | $3.34 | +0.60% | $5.2B | — |
Source: Financial Modeling Prep · peers by sector/industry